Autopsy report · NCT05085964
An Open-Label Extension Study to Evaluate Safety & Tolerability of QR-421a in Subjects With Retinitis Pigmentosa
Cause of deathFunding or business
“The sponsor decided to terminate the study early”
Life of this trial
- Ran for about 1 year 1 month before it stopped.
- 21 participants enrolled.
- Results were posted on the registry 2 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- Laboratoires Thea
- Sponsor type
- Industry
- Conditions
- Retinitis Pigmentosa; Usher Syndrome Type 2
- Interventions
- RNA antisense oligonucleotide for intravitreal injection
- Participants
- 21
- Sites
- 7
- Countries
- Canada, France, United States
Trials that died the same way
- Phase 1 Trial of RP-3467 Alone and in Combination With Olaparib in Participants With Advanced Solid Tumors
“Sponsor decided to terminate study early” - A Study of ABP 215 Versus Bevacizumab in Chinese Subjects With Advanced Non-Squamous Non-Small Cell Lung Cancer
“Sponsor decision to early terminate the study” - Study of RP-6306 With FOLFIRI in Advanced Solid Tumors
“Sponsor decided to terminate the study” - A Study to Assess Recurrence of Actinic Keratosis in Participants Treated With Methyl Aminolevulinate Hydrochloride Cream or Vehicle Cream Who Achieved Complete Response to Treated Lesions in Earlier Study
“The study was terminated early as per Sponsor's decision” - Efficacy and Safety of Etrasimod (APD334) in Inflammatory Bowel Disease Patients With Active Skin Extra-intestinal Manifestations
“Sponsor decision to terminate the study”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.